Therefore, men with VHR-2 prostate cancer experience unusually aggressive oncologic outcomes and should be considered for intensive follow-up for metastasis using state-of-the-art technologies such as prostate-specific membrane antigen positron emission tomography scan [27] and/or adjuvant/earlier intervention with effective systemic therapy, such as docetaxel Abiraterone and Enzalutamide, in addition to longer periods of ADT use [28], that is, clinical trial settings using multimodal treatment. The gene discussed is FOLH1; the disease is prostate carcinoma.